One possible explanation is that sparse, or ‘seeding' methylation at ESR1-responsisive enhancer sites in primary tumours could reflect a propensity to gain extensive methylation that spreads as resistance develops, which then becomes firmly established in recurrent disease (as discussed in ref. 39). This evidence concerns the gene ESR1 and neoplasm.